Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07014150
Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
An Exploratory Study on the Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Sponsor: Peking Union Medical College Hospital
Conditions
Hepatocellular Carcinoma Resectable
Interventions
Iparomlimab and Tuvonralimab Lenvatinib
Updated 1 time since 2025 Last updated: Jun 8, 2025 Started: Jun 10, 2025 Primary completion: May 1, 2027 Completion: May 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Hepatocellular Carcinoma Resectable and is currently actively recruiting participants. Peking Union Medical College Hospital leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peking Union Medical College Hospital
Data source: Peking Union Medical College Hospital
For direct contact, visit the study record on ClinicalTrials.gov .